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Abstract
Introduction: Gender, age, physiology (GAP) system have proven to be an easy tool for 
predicting disease stages and survival in idiopathic pulmonary fibrosis (IPF) patients.
Objective: To validate mortality risk as determined by the GAP system in a real‐life 
multicentre IPF population treated with pirfenidone.
Methods: The study included patients who received pirfenidone for at least 6 months. 
The GAP calculator and the GAP index were determined. The primary outcome was 
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1 |  INTRODUCTION
In recent years, there has been a growing interest in scores 
that allow to determine the severity of patients with idiopathic 
pulmonary fibrosis (IPF) to assess the prognosis, to evalu-
ate possible treatment options including timing to transplant 
and to standardize cohorts of patients in controlled clinical 
studies.1-6 Among a number of different methods, the gender, 
age, physiology (GAP) index and the GAP calculator for the 
GAP Risk Assessment System (GAP system) have proven to 
be the most easy and applicable tool in the current clinical 
practice1; however, there are still only few studies that have 
assessed their applicability and usefulness in daily practice. 
Furthermore, ethnicity has been reported as a factor that 
can influence the reliability of these two scoring systems, 
as demonstrated by the Korean and Japanese experiences.7,8 
Indeed, up until now most of the data have been derived from 
American studies.1 Finally, to our knowledge, there are still 
very few clinical trials that have evaluated the applicability of 
the GAP system in the era of antifibrotic therapies.9,10
We herewith report an Italian national multicentre expe-
rience aimed to validate the predictive value of the risk of 
death determined by these two indicators in a retrospective 
analysis of a cohort of patients with IPF who received pirfeni-
done, the first antifibrotic drug marketed for the treatment of 
this disease.
2 |  MATERIALS AND METHODS
2.1 | Patient population and study design
The study sample herewith considered is in part derived from 
a previous retrospective observational study carried out on 
continuous patients diagnosed with mild, moderate and se-
vere IPF and treated with pirfenidone in the period between 
April 2011 and January 201311; the study involved 12 intersti-
tial lung disease centres across Italy that joined the European 
Named Patient Access Program (NPP). The Company that 
was involved in the development and marketing of pirfeni-
done in Europe has supported this programme: InterMune 
Inc. has in fact allowed qualified physicians to make the 
newly approved pirfenidone available to their IPF patients, 
provided that pre‐specified medical criteria and conditions 
were met, before it was commercially available within a 
given European country. The drug was made available to 
patients free of charge. Patients who had received steroids, 
azathioprine or N‐acetylcysteine (NAC) before pirfenidone 
therapy initiation were not excluded from the analysis; aza-
thioprine and NAC were stopped before treatment with pi-
rfenidone, low‐dose steroids (<15 mg/day) were continued 
in some patients. Data of patients who had been enrolled in 
the CAPACITY trials and subsequently entered the NPP pro-
gramme were also included.11
All patients who received at least 6 months of treatment 
with the new antifibrotic drug and who had pulmonary func-
tion data available at 6 months after pirfenidone initiation 
where included in the study and followed up. The diagnosis 
of IPF was performed with criteria of the statement of ATS/
ERS/JRS/ALT in 2011.12
The primary outcome was all‐cause mortality ascertained. 
Lung transplantation was treated as a competing risk.
The GAP Risk Assessment System,1 which combines 
commonly measured clinical (age and gender) and phys-
iologic variables, forced vital capacity (FVC) and capac-
ity of the lung for carbon monoxide (DLCO), was used as 
predictor variable. The individual risk calculator (the GAP 
calculator) and the staging system (the GAP index) were 
evaluated after 6 months of pirfenidone therapy. The for-
mula of the GAP calculator is described in the Appendix 
(online material).
all‐cause mortality. The prognostic accuracy of the GAP system was evaluated with 
respect to calibration and discrimination.
Results and Conclusion: Sixty‐eight IPF patients were enrolled in the study. The 
median follow‐up was 2.4 years (range 0.1‐7.4 years). A total of 22 deaths as first 
event (32%) and of 10 lung transplantation (15%) were recorded. The cumulative in-
cidence of mortality at 1, 2 and 3 years was 10.4%, 22.4% and 38.4%, respectively. 
The differences between the predicted and observed mortality were not significant for 
the GAP index while the observed mortality become comparable to that predicted by 
the GAP calculator only in the third year of follow‐up. The C‐index for the GAP 
index was 0.74 (95% CI 0.57‐0.93) while the C‐statistic value for the GAP calculator 
was 0.77 (95% CI 0.59‐0.95).
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Purpose of this study was the validation of the GAP sys-
tem evaluated after 6 months of pirfenidone therapy in pre-
dicting the subsequent risk of death in an Italian population 
of patients affected by IPF.
This study was approved by the San Giuseppe Hospital 
Ethical Committee (protocol number 27/13) and patient’s 
confidentiality was maintained.
2.2 | Statistical analysis
Patients were followed up after 6 months of pirfenidone treat-
ment. Vital status was ascertained by each participating cen-
tre until July 2015.
Mortality risk was estimated in terms of cumulative inci-
dence failure (CIF) taking into account lung transplantation 
as a competing cause of event. The Gray’s test was used to 
assess cumulative incidence differences between groups.
Using the GAP Risk Assessment System1 the predicted 
1‐, 2‐ and 3‐yearr risk of death after 6 months of pirfenidone 
treatment has been calculated for each patient in the cohort. 
The GAP system consists in a point scoring stage model 
(GAP index) and a continuous calculator (GAP calculator) 
derived from variables available at study entry (clinical visit 
at 6 months after pirfenidone treatment).
The prognostic accuracy of the GAP system was evalu-
ated with respect to discrimination and calibration.
Discrimination was measured by the Harrell’s concor-
dance statistics (c‐index), which is the probability that given 
two randomly selected patients, the survival time predicted 
by the GAP system is greater for the subject who survived 
longer. A value of one denotes perfect concordance, while a 
value of 0.5 is no better than chance.
Calibration was evaluated by a visual inspection of the 
plot comparing the 1‐, 2‐ and 3‐year average mortality 
predicted by the GAP model with cumulative incidence 
of mortality observed in groups defined by the GAP stage 
(ie, stage I, stage II and stage III). The Hosmer‐Lemeshow 
test was used to formally compare predicted and observed 
risks.
All statistical analyses were performed with SAS soft-
ware, version 9.3 (SAS Institute Inc., Cary, North Carolina) 
and R‐software (R Foundation for Statistical Computing, 
Vienna, Austria). A P value < 0.05 was considered statisti-
cally significant. All reported P values are two‐sided.
3 |  RESULTS
Sixty‐eight IPF patients treated for at least 6 months with pi-
rfenidone were studied. The characteristics of the sample are 
shown in Table 1.
Pulmonary function profile and stratification of the 
population based on GAP severity index, as well as GAP 
calculator, of studied sample at 6 months after pirfenidone 
treatment is reported in Table 2.
The median duration of follow‐up time, which started 
from the sixth month of treatment, was 2.4 years (range 
0.1‐7.4 years). A total of 22 deaths as first event (32%) and 
of 10 lung transplantation (15%) occurred during follow‐up. 
The cumulative incidence of mortality at 1, 2 and 3 years 
was 10.4% (95% CI: 4.6%‐19.2%), 22.4% (13.2%‐33.0%) and 
38.4% (95% CI 24.9%‐51.7%), respectively (Figure 1).
Mortality risk was significantly different according to GAP 
index stage (Gray’s test P < 0.0001). The cumulative inci-
dence of mortality at 3 years was 14.8% (95% CI 1.7%‐40.8%) 
for stage I, 36.9% (95% CI 20.0%‐53.9%) for stage II and 80% 
(95% CI 32.6%‐95.7%) for stage III (Figure 2).
The cumulative incidence of mortality observed among 
the study sample and that predicted by the GAP Risk 
Assessment System were reported in Table 3 separately by 
year of follow‐up and stratified by GAP stage.
The risk of death predicted by the GAP system was com-
pared with the observed mortality using calibration plots 
(Figures 3 and 4).
The observed cumulative incidence of mortality for stage 
I and for stage II was lower while, for stage III was higher 
than mortality predicted by both the GAP index and the GAP 
calculator at each year of follow‐up. However, while the GAP 
T A B L E  1  Patients’ characteristics (N = 68)
Characteristic Levels N (%)
Gender Female 16 (24)
Male 52 (76)
Age (years)* ≤60 7 (10)
61‐65 12 (18)
>65 49 (72)
Smoking status Ex‐smoker 50 (74)
Non‐smoker 15 (22)
Smoker 3 (4)
Histological diagnosis No 49 (72)
Yes 19 (28)
Cortisone No 27 (40)
Yes 41 (60)
Azathioprine No 50 (74)
Yes 18 (26)
N‐Acetylcysteine No 38 (56)
Yes 30 (44)
Time from diagnosis of IPF to start of 
pirfenidone therapy (years)** 
<1 22 (32)
1‐2 24 (35)
>2 22 (32)
*Mean age: 69 years (SD: 7.9 years). 
**Mean time from diagnosis of IPF to initiation of treatment with pirfenidone: 2 
years (SD: 1.9 years). 
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index was quite precise in predicting mortality and the dif-
ferences between the predicted and observed risks were not 
significant (Hosmer‐Lemeshow P = 0.088, P = 0.218 and 
P = 0.778 at 1, 2, and 3 years, respectively), the observed 
mortality becomes comparable to that predicted by GAP 
calculator only in the third year of follow‐up (Hosmer‐
Lemeshow P = 0.014, P = 0.019 and P = 0.061 at 1, 2, and 
3 years, respectively).
The C index for the GAP index was 0.74 (95% CI 
0.57‐0.93) while the C statistic value for the GAP calculator 
was 0.77 (95% CI 0.59‐0.95).
The median difference of the GAP index before and after 
the administration of pirfenidone was equal to zero.
4 |  DISCUSSION
This is the first study investigating the use of the GAP sys-
tem, a validated tool to assess mortality risk, in the era of 
antifibrotic therapies in a national multicentre case series 
of real‐life patients with IPF. The use of a simple staging 
system is very important to properly plan the therapeutic ac-
tions and some important decisions, such as the timing for 
lung transplantation and in helping clinicians to more ac-
curately counsel patients with IPF.1-6 Being able to assess 
the clinical course and response to therapy of individual IPF 
patients is still both an open issue and a major objective to be 
achieved. The difficulty stems from the fact that the course 
of the disease is extremely variable for each individual pa-
tient. Reliable prognostic indicators have therefore not yet 
T A B L E  2  GAP index and GAP calculator of patients at study 
entry (6 months after pirfenidone therapy) (N = 68)
Predictor N (%) Median, (min‐max)
G—Gender Female 16 (24)
Male 52 (76)
A—Age class ≤60 7 (10)
61‐65 12 (18)
>65 49 (72)
Physiology FVC %
>75 29 (43)
50‐75 35 (51)
<50 4 (6)
DLCO %
>55 14 (21)
36‐55 30 (44)
≤35 24 (35)
GAP index 4 (2‐7)
GAP Risk 
Assessment 
System
Stage I (GAP 
index 0‐3)
21 (31)
Stage II (GAP 
index 4‐5)
37 (54)
Stage III 
(GAP index 
6‐8)
10 (15)
GAP 
calculator 
1‐y mortality 
2‐y mortality 
3‐y mortality
16.3 (4.4‐35.5)
31.9 (9.2‐61.2)
45.4 (14.1‐77.6)
F I G U R E  1  Cumulative incidence of 
mortality from study entry (6 months after 
pirfenidone initiation) Years from study entry (6 months after pirfenidone initiation)
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been identified.9 Guidelines consider the variations of FVC 
as an indicator of response to therapy and as a prognostic 
indicator, but this topic is still subject to much debate.12-19 
Some authors have found significant mortality also in pa-
tients with stable FVC5 and it has recently been reported that 
a 10% decline in FVC during pirfenidone therapy does not 
necessarily represent a treatment failure. Indeed, patients 
who continue getting pirfenidone despite progression of the 
disease may not experience further decline of FVC.19 The 
GAP index and disease staging system has been proposed 
as a quick and simple prognostic tool for estimating mortal-
ity risk in patients with IPF, while the GAP calculator is a 
tool to estimate individuals’ risk.1 In this real‐life study con-
ducted in patients treated with pirfenidone, the GAP system 
proved to be a reliable tool to predict mortality at 3 years. It 
seemed less sensitive at 1 and 2 years. The observed cumu-
lative incidence of mortality for stage I and II patients was 
lower than the mortality predicted by both the GAP index 
and the GAP calculator for all follow‐up time points. On 
the contrary, it was higher for stage III patients. The GAP 
index was quite accurate in predicting mortality, and the dif-
ferences between the predicted and observed mortality were 
not significant (Hosmer‐Lemeshow P = 0.088, P = 0.218 
and P = 0.778 at 1, 2, and 3 years, respectively). However, 
the observed mortality became comparable to that predicted 
by the GAP calculator only in the third year of follow‐up 
(Hosmer‐Lemeshow P = 0.014, P = 0.019 and P = 0.061 
at 1, 2 and 3 years, respectively).The discrimination abil-
ity of the GAP index and the GAP calculator in our study 
was slightly higher than those obtained both in the original 
article1 and in the validation study among Korean patients7 
(c‐index 0.74 vs 0.70 and 0.66, respectively, for the GAP 
index; c‐index 0.77 vs 0.69 and 0.68, respectively, for the 
GAP calculator).
F I G U R E  2  Cumulative incidence of 
mortality by GAP index stage from study 
entry (6 months after pirfenidone initiation) Years from study entry (6 months after pirfenidone initiation)
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Gray test p−value: <0.0001
Stage I, (N=21)
Stage II (N=37)
Stage III (N=10)
Year GAP stage
Predicted by 
GAP index
Predicted by GAP 
calculator Observed
1 I 5.6 8.4 0.0
II 16.2 17.2 5.5
III 39.2 25.8 50.0
2 I 10.9 17.6 4.7
II 29.9 34.2 19.4
III 62.1 48.4 70.0
3 I 16.3 28.3 14.8
II 42.1 51.2 36.9
III 76.8 67.8 80.0
T A B L E  3  Comparison of predicted 
and observed cumulative incidence of 
mortality
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Studies have shown that the use of pirfenidone reduces 
pulmonary function loss at all stages of the disease (patients 
with FVC > 80% were compared to patients with FVC ≤ 
80% and patients in GAP I stage were compared to patients 
in GAP II and III stages)9,20; on the other hand, FVC is con-
sidered a surrogate endpoint of mortality.14-18 In our study, 
the observed mortality was lower than the expected mortality 
in the GAP I and II stages the first 2 years and higher in the 
GAP III stage. This could be attributed to the different prev-
alence and influence of comorbidities in the various patient 
groups. Comorbidities may represent an additional factor to 
be taken into account for the GAP system to have a clini-
cal relevance as a prognostic tool. Comorbidities may add 
their effect to age, gender and pulmonary function thereby 
modifying the overall mortality. This could explain why the 
GAP system might not be fully applicable when considering 
patients coming from real‐life studies, with different comor-
bidities compared to clinical trial patients, who may have 
been selected based on exclusion criteria.21,22 However, this 
remains a hypothesis as the presence of comorbidities has not 
yet been analysed for our study.
A pooled analysis of the data from phase III pirfenidone 
studies (CAPACITY and ASCEND) showed that pirfeni-
done significantly reduced all‐cause mortality and IPF treat-
ment‐related mortality at 1 year.23 The reduction in mortality 
observed in GAP I and II stage patients could therefore be 
attributed to a greater effect of therapy in the first 2 years of 
treatment. The difference observed in GAP III stage patients 
may be unreliable because of the small number of individuals 
in this group of seriously ill patients.
Our study has all the known limits and all the bias of a 
retrospective research, but it also possesses the strengths of 
real‐life studies. The other major limitation of our study is 
the small number of patients. However, our work describes a 
population certainly representative of the disease in a major 
European nation. All Italian centres that were considered in 
the study had participated in the NPP programme and repre-
sent the most important reference centres for diagnosis and 
treatment of interstitial diseases. The follow‐up period was 
long enough and suitable (2.4 years) and the average sur-
vival recorded was of 3.7 years from the time of diagnosis, in 
line with the IPF experience and comparable to the Korean 
F I G U R E  3  GAP index calibration plots. The x‐axis shows the 1‐year A, 2‐year B, and 3‐year C, cumulative incidence of mortality as 
predicted by the GAP model, and the y‐axis shows the observed mortality. Every point represents a GAP stage. The solid line represents perfect 
agreement between predicted and observed mortality
F I G U R E  4  GAP calculator calibration plots. The x‐axis shows the 1‐year A, 2‐year B, and 3‐year C, cumulative incidence of mortality as 
predicted by the GAP model, and the y‐axis shows the observed mortality. Every point represents a GAP stage. The solid line represents perfect 
agreement between predicted and observed mortality
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series.7 However, differences emerge from the comparison of 
this latest study and our own data. While the Koreans have in 
fact found differences in the calculation of the 2‐year mor-
tality and particularly at the 3‐year mark, we instead had the 
opposite experience: being the figure predicted at 3 years the 
closest to real.
Significant differences do however exist between the two 
studies: in 17.9% of Korean patients the diffusion value was 
missing, while we instead only considered patients for whom 
a complete set of data was available. Furthermore, we only 
assessed patients taking pirfenidone while the Korean trial 
did not specify what therapy patients were following. Most 
probably, being this a cohort studied between 2005 and 2009 
nobody was taking pirfenidone. Also in our experience, the 
GAP system proves to be a good staging system able to dis-
criminate well among the three different risk classes.
The GAP system is a simple‐to‐use disease staging sys-
tem. It has found more applications than the previously 
proposed prediction models, which so far have had little 
impact in the daily clinical practice. This might be because 
of their complexity, time‐consuming character or because 
they were never validated.2-4,24,25 The difference between 
the predicted and observed variables in our study popula-
tion suggests that there may have been important factors 
(eg, nature of IPF treatment or comorbidities) that were 
not captured by the GAP model. Additional studies would 
be valuable to determine the impact of treatment on model 
performance. This study was the first to evaluate the GAP 
system in the era of antifibrotic therapies and analyse its 
reliability in a multicentre Italian real‐life population of 
patients treated with pirfenidone for almost 6 months. Our 
results raise some concerns about the use of GAP system 
in the clinical practice that deserve further study.The GAP 
model showed a similar discrimination index in our study 
population compared to Ley et al.1 However, the GAP cal-
culator did not accurately predict the 1‐ and 2‐year mortal-
ity in individual patients with IPF treated with pirfenidone. 
In our cohort, the GAP system was more accurate in pre-
dicting mortality than the GAP calculator. The reassess-
ment of the GAP system in the era of new therapies for IPF 
is an important topic: we hope we gave our small contri-
bution to have begun to address this new frontier that will 
anyway require further validation studies.
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